Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Virginia Bellido, Carel W le Roux, Elif I Ekinci et al.
✦ AI-curated · Sources linked
In 30 seconds
TRIUMPH-2 was a double-blind, parallel-group, randomised, placebo-controlled phase 3 trial at 92 centres in eight countries. It assessed once-weekly retatrutide in adults with obesity and type 2 diabetes. At week 80, mean bodyweight change was -11·9% with 4 mg, -16·8% with 9 mg, and -18·8% with 12 mg, compared with -5·1% with placebo. The estimated treatment differences versus placebo were -6·9%, -11·8%, and -13·8%, respectively (p<0·0001 for all). Gastrointestinal adverse events were more common with retatrutide.
Key findings
- At week 80, bodyweight changed by -18·8% with retatrutide 12 mg versus -5·1% with placebo.
- Estimated bodyweight treatment differences versus placebo were -6·9% with 4 mg, -11·8% with 9 mg, and -13·8% with 12 mg (p<0·0001 for all).
- Diarrhoea occurred in 27–34% of retatrutide recipients versus 13% with placebo; nausea occurred in 14–28% versus 8%.
- Permanent treatment discontinuation due to adverse events or death was reported in 12% with 9 mg and 8% with 12 mg, versus 4% with 4 mg and 5% with placebo.
Why it matters
The trial provides phase 3 evidence that retatrutide can produce substantial weight reduction in adults with obesity and type 2 diabetes, a population in whom weight management is clinically important. The greater weight loss at higher doses occurred alongside more gastrointestinal adverse events and higher discontinuation at the 9 mg and 12 mg doses, so efficacy and tolerability both inform interpretation.
What to keep in mind
The abstract reports outcomes through week 80; longer-term effects and safety are not established here. The findings apply to adults meeting the trial’s eligibility criteria and background-treatment conditions.